Many attempts have been made to find genetic abnormalities inducing carcinogenesis after the development of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor targeting EGFR in lung cancer. New target therapies have been already commercialized and studied along with the recent discovery of gene rearrangement involved in the carcinogenic process of non-small cell lung cancer. This study aims to investigate anplastic lymphoma kinase, c-ros oncogene 1, and receptor tyrosine kinase, in particular. © 2013 The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.
CITATION STYLE
Choi, C. M. (2013). Overview of ALK and ROS1 rearranged lung cancer. Tuberculosis and Respiratory Diseases. https://doi.org/10.4046/trd.2013.75.6.236
Mendeley helps you to discover research relevant for your work.